The lead compound, which is positioned for clinical trials within a year, targets a key mechanism that determines whether cells, particularly those in tumors, grow and proliferate.
Dale Johnson, president and CEO of Emiliem, said: “This is a seminal moment in the history of our company. Not only do we gain a well-researched molecule at an advanced preclinical stage, but this also enables us to focus our internal discovery efforts including medicinal chemistry and early stage development activities around the PI3K/Akt/mTOR pathway, a series of biological events that control protein synthesis, angiogenesis, and cell cycle progression.”